Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT Combination With Tislelizumab in Advanced or Metastatic NSCLC
NCT07432984Phase 2Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Oct 2028
- Modality
- Live Biotherapeutic Products, Monoclonal Antibodies
01
Overview
A Phase 2 trial of tislelizumab, fecal microbiome transplant in non-small cell lung cancer (NSCLC). Planned start Sep 2026; status: not yet recruiting.
02
Drugs
tislelizumabfecal microbiome transplant
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07432984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07432984.